SETTING: A public tuberculosis (TB) referral hospital in KwaZulu-Natal, South Africa. OBJECTIVE: To present treatment outcomes of patients with extensively drug-resistant tuberculosis (XDR-TB) patients and human immunodeficiency virus (HIV) coinfection with and without highly active antiretroviral therapy. METHODS: Retrospective cohort study. Eligible patients had drug susceptibility testing that met a consensus definition for XDR-TB, and agreed to treatment. Therapy was based on drug susceptibilities, available medications and patient tolerance. RESULTS: Overall, 60 XDR-TB patients initiated therapy with a median number of 5.5 drugs. Of these, 43 (72%) were HIV-positive, and 21 (49%) were on antiretroviral therapy; 29 HIV-infected patients (67%) had available CD4 counts, with a median CD4 count of 200.5 cells/mm(3) (standard deviation 127.4 cells/mm(3)). Of 60 patients, 31 (52%) had adverse events (AEs), and 17/60 patients (28%) had severe AEs. During follow-up, 12/60 (20%) experienced sputum culture conversion, while 25/60 (42%) patients died. None of the following was significantly associated with mortality: HIV status, previous MDR diagnosis or severe AEs. DISCUSSION: In this study, it was possible to treat HIV-XDR-TB coinfected patients and prolong survival in a resource-limited setting. We highlight the challenges in treatment, including high frequencies of AEs and death. Expanded identification of cases, prompt referral for treatment, and attention to management of comorbidities may facilitate successful treatment of XDR-TB in HIV-infected patients.
SETTING:A public tuberculosis (TB) referral hospital in KwaZulu-Natal, South Africa. OBJECTIVE: To present treatment outcomes of patients with extensively drug-resistant tuberculosis (XDR-TB) patients and human immunodeficiency virus (HIV) coinfection with and without highly active antiretroviral therapy. METHODS: Retrospective cohort study. Eligible patients had drug susceptibility testing that met a consensus definition for XDR-TB, and agreed to treatment. Therapy was based on drug susceptibilities, available medications and patient tolerance. RESULTS: Overall, 60 XDR-TBpatients initiated therapy with a median number of 5.5 drugs. Of these, 43 (72%) were HIV-positive, and 21 (49%) were on antiretroviral therapy; 29 HIV-infectedpatients (67%) had available CD4 counts, with a median CD4 count of 200.5 cells/mm(3) (standard deviation 127.4 cells/mm(3)). Of 60 patients, 31 (52%) had adverse events (AEs), and 17/60 patients (28%) had severe AEs. During follow-up, 12/60 (20%) experienced sputum culture conversion, while 25/60 (42%) patients died. None of the following was significantly associated with mortality: HIV status, previous MDR diagnosis or severe AEs. DISCUSSION: In this study, it was possible to treat HIV-XDR-TB coinfectedpatients and prolong survival in a resource-limited setting. We highlight the challenges in treatment, including high frequencies of AEs and death. Expanded identification of cases, prompt referral for treatment, and attention to management of comorbidities may facilitate successful treatment of XDR-TB in HIV-infectedpatients.
Authors: Giovanni Battista Migliori; Christoph Lange; Enrico Girardi; Rosella Centis; Giorgio Besozzi; Kai Kliiman; Johannes Ortmann; Alberto Matteelli; Antonio Spanevello; Daniela M Cirillo Journal: Clin Infect Dis Date: 2008-03-15 Impact factor: 9.079
Authors: C Dye; A Bassili; A L Bierrenbach; J F Broekmans; V K Chadha; P Glaziou; P G Gopi; M Hosseini; S J Kim; D Manissero; I Onozaki; H L Rieder; S Scheele; F van Leth; M van der Werf; B G Williams Journal: Lancet Infect Dis Date: 2008-01-16 Impact factor: 25.071
Authors: Giovanni Battista Migliori; Johannes Ortmann; Enrico Girardi; Giorgio Besozzi; Christoph Lange; Daniela M Cirillo; M Ferrarese; Giuseppina De Iaco; Andrea Gori; Mario C Raviglione Journal: Emerg Infect Dis Date: 2007-05 Impact factor: 6.883
Authors: Carole D Mitnick; Sonya S Shin; Kwonjune J Seung; Michael L Rich; Sidney S Atwood; Jennifer J Furin; Garrett M Fitzmaurice; Felix A Alcantara Viru; Sasha C Appleton; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Sharon Choi; Molly F Franke; Hamish S F Fraser; Dalia Guerra; Rocio M Hurtado; Darius Jazayeri; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Alexander Sloutsky; Mercedes C Becerra Journal: N Engl J Med Date: 2008-08-07 Impact factor: 91.245
Authors: G B Migliori; C Lange; R Centis; G Sotgiu; R Mütterlein; H Hoffmann; K Kliiman; G De Iaco; F N Lauria; M D Richardson; A Spanevello; D M Cirillo Journal: Eur Respir J Date: 2008-06 Impact factor: 16.671
Authors: N Padayatchi; M Gopal; R Naidoo; L Werner; K Naidoo; I Master; M R O'Donnell Journal: J Antimicrob Chemother Date: 2014-06-30 Impact factor: 5.790
Authors: Max R O'Donnell; Alexander Pym; Paras Jain; Vanisha Munsamy; Allison Wolf; Farina Karim; William R Jacobs; Michelle H Larsen Journal: J Clin Microbiol Date: 2015-04-29 Impact factor: 5.948
Authors: Keertan Dheda; Tawanda Gumbo; Neel R Gandhi; Megan Murray; Grant Theron; Zarir Udwadia; G B Migliori; Robin Warren Journal: Lancet Respir Med Date: 2014-03-24 Impact factor: 30.700
Authors: N R Gandhi; J R Andrews; J C M Brust; R Montreuil; D Weissman; M Heo; A P Moll; G H Friedland; N S Shah Journal: Int J Tuberc Lung Dis Date: 2012-01 Impact factor: 2.373
Authors: M Loveday; K Wallengren; A Voce; B Margot; T Reddy; I Master; J Brust; K Chaiyachati; N Padayatchi Journal: Int J Tuberc Lung Dis Date: 2012-02 Impact factor: 2.373
Authors: Jennifer R Zelnick; Andrew Gibbs; Marian Loveday; Nesri Padayatchi; Max R O'Donnell Journal: J Public Health Policy Date: 2013-05-30 Impact factor: 2.222
Authors: Max R OʼDonnell; Allison Wolf; Lise Werner; C Robert Horsburgh; Nesri Padayatchi Journal: J Acquir Immune Defic Syndr Date: 2014-09-01 Impact factor: 3.731